Figure 4 : IYIY-I2-BODIPY increases CD4+ and CD8+ T-lymphocytes expressing IFN-γ and IL-17.

From: Tropomyosin Receptor Kinase C Targeted Delivery of a Peptidomimetic Ligand-Photosensitizer Conjugate Induces Antitumor Immune Responses Following Photodynamic Therapy

Figure 4

4T1 tumor bearing mice were randomly divided into four treatment groups (saline, I2-BODIPY, YIYI-I2-BODIPY and IYIY-I2-BODIPY) and compounds were administrated via tail vein respectively. Mice were then sacrificed at 2 h and 24 h post compound administration. TDLN and tumor tissues were isolated to generate single cells suspension. The suspension cells were activated using PMA/Ionomycin/golgi plug as described in Methods and Materials. Upon activation, CD4 marker was stained, followed by fixation and permeabilization for intracellular staining. (a) Th1 cells were stained with fluorescence conjugated anti-IFN-γ, (b) Th17 with anti-IL-17. CD8 marker was stained, follow by intracellular staining with (c) anti-IFN-γ (CTL) and (d) anti-IL-17 (Tc17). Each group of cells was then quantified using flow cytometry. Data represent mean ± SEM with minimum of four mice per group. *p < 0.05 vs I2-BODIPY using One-way ANOVA (Dunnett’s test).